LATS2 and neoplasm: Furthermore, we found that in 36.7% of cases, the LATS2 promoter is methylated in NPC tumor tissues, while the LATS2 promoter was found to be methylated in all the chronic nasopharyngeal inflammation epithelium samples evaluated (100%).